Alx oncology realigns executive leadership team

South san francisco, calif., sept. 06, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today announced that jason lettmann, a member of the board of directors, will succeed jaume pons, ph.d. as chief executive officer, effective september 6, 2023. dr. pons will transition to the role of chief scientific officer and remain president and both executives will remain members of the board of directors.
ALXO Ratings Summary
ALXO Quant Ranking